Nitric oxide 100ppm
Nitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Nitric oxide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Nitric oxide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(11)
Specialist neonatal respiratory care for babies born preterm (NG124)
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment (HTG776)
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
Thora-3Di for assessing asthma in children (MIB122)
Reslizumab for treating severe eosinophilic asthma (TA479)
Inducing labour (NG207)
Tezepelumab for treating severe asthma (TA880)
Smartinhaler for asthma (MIB90)
Hypertension in pregnancy: diagnosis and management (NG133)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 50 · 1990–2022
Showing the 50 most relevant studies, sorted by most relevant.
U. Förstermann, N. Xia, Huige Li
Circulation Research, 2017
R. Radi
Proceedings of the National Academy of Sciences, 2018
Maris A. Cinelli, H. Do, Galen P. Miley, et al.
Medicinal research reviews, 2019
C. Farah, L. Michel, J. Balligand
Nature Reviews Cardiology, 2018
J. Lundberg, E. Weitzberg
Cell, 2022
K. Barrington, N. Finer, T. Pennaforte, et al.
The Cochrane database of systematic reviews, 2017
Pol Picón-Pagès, Joan Garcia-Buendia, F. J. Muñoz
Biochimica et biophysica acta. Molecular basis of disease, 2019
A. Shapiro
Vitamins and hormones, 2021
M. Carlström
Nature Reviews. Nephrology, 2021
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
10 found
Half-life
Not available
Mechanism
Nitric oxide is a compound produced by many cells of the body.
Food interactions
None known
Human targets
6 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
6 seconds
Metabolism
Elimination
70%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant.
The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 988 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:17671174
Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses .
PMID:25691885
Tryptophan shortage inhibits T lymphocytes division and accumulation of tryptophan catabolites induces T-cell apoptosis and differentiation of regulatory T-cells .
PMID:25691885
Acts as a suppressor of anti-tumor immunity .
PMID:14502282 PMID:23103127 PMID:25157255 PMID:25691885
Limits the growth of intracellular pathogens by depriving tryptophan .
PMID:25691885
Protects the fetus from maternal immune rejection PMID:25691885
Enzymes involved in drug metabolism — important for understanding drug interactions
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
ATC R07AX01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Nitric Oxide
Matched from: Nitric oxide
Additional database identifiers
Drugs Product Database (DPD)
16163
ChemSpider
127983
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4684
GeneCards
GUCY1A2
GenBank Gene Database
X63282
GenBank Protein Database
31671
UniProt Accession
GCYA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6059
GenAtlas
INDO
GeneCards
IDO1
GenBank Gene Database
M34455
GenBank Protein Database
306956
Guide to Pharmacology
2829
UniProt Accession
I23O1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4687
GeneCards
GUCY1B1
Guide to Pharmacology
1290
UniProt Accession
GCYB1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4685
GeneCards
GUCY1A1
Guide to Pharmacology
1288
UniProt Accession
GCYA1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7393
GeneCards
MT1A
UniProt Accession
MT1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7876
GenAtlas
NOS3
GeneCards
NOS3
GenBank Gene Database
M93718
GenBank Protein Database
189212
Guide to Pharmacology
1249
UniProt Accession
NOS3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:404
GenAtlas
ALDH2
GeneCards
ALDH2
GenBank Gene Database
X05409
GenBank Protein Database
28606
Guide to Pharmacology
2595
UniProt Accession
ALDH2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2615
GeneCards
CYP2B6
GenBank Gene Database
M29874
GenBank Protein Database
181296
Guide to Pharmacology
1324
UniProt Accession
CP2B6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q207843), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.